

Cosentyx® (secukinumab) (Subcutaneous)

Document Number: IC-0229

Last Review Date: 08/03/2021

Date of Origin: 02/24/2015

Dates Reviewed: 02/2015, 01/2016, 01/2017, 01/2018, 08/2018, 08/2019, 03/2020, 07/2020, 07/2021, 08/2021

I. Length of Authorization

Coverage will be provided for six months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Cosentyx 150 mg Sensoready Pen/prefilled syringe/single-use vial:
 - Loading: 2 pens/prefilled syringes/vials at weeks 0, 1, 2, 3, 4
 - Maintenance: 2 pens/prefilled syringes/vials every 28 days
- Cosentyx 75 mg prefilled syringe (for pediatric patients less than 50 kg):
 - Loading: 1 prefilled syringe at weeks 0, 1, 2, 3, 4
 - Maintenance: 1 prefilled syringe every 28 days

B. Max Units (per dose and over time) [HCPCS Unit]:

Indication	Max Units
Non-Radiographic Axial Spondyloarthritis	<u>Loading:</u> <ul style="list-style-type: none">• 150 mg at weeks 0, 1, 2, 3, 4 <u>Maintenance:</u> <ul style="list-style-type: none">• 150 mg every 28 days
All Other Indications	<u>Loading:</u> <ul style="list-style-type: none">• 300 mg at weeks 0, 1, 2, 3, 4 <u>Maintenance:</u> <ul style="list-style-type: none">• 300 mg every 28 days

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 18 years of age, unless otherwise specified; **AND**
- Physician has assessed baseline disease severity utilizing an objective measure/tool; **AND**

Universal Criteria ¹

- Patient has been evaluated and screened for the presence of latent tuberculosis (TB) infection prior to initiating treatment and will receive ongoing monitoring for presence of TB during treatment; **AND**
- Must not be administered concurrently with live vaccines; **AND**
- Patient does not have an active infection, including clinically important localized infections; **AND**
- Patient is not on concurrent treatment with another TNF-inhibitor, biologic response modifier or other non-biologic immunomodulating agent (i.e., apremilast, tofacitinib, baricitinib, etc.); **AND**

Plaque Psoriasis † ^{1,13,26,32-34}

- Documented moderate to severe plaque psoriasis for at least 6 months with at least one of the following:
 - Involvement of at least 3% of body surface area (BSA); **OR**
 - Psoriasis Area and Severity Index (PASI) score of 10 or greater; **OR**
 - Incapacitation or serious emotional consequences due to plaque location (i.e., hands, feet, head and neck, or genitalia, etc.) or with intractable pruritis; **AND**
- Patient did not respond adequately (or is not a candidate) to a 4 week minimum trial of topical agents (i.e., anthralin, coal tar preparations, corticosteroids, emollients, immunosuppressives, keratolytics, retinoic acid derivatives, and/or Vitamin D analogues); **AND**
- Patient did not respond adequately (or is not a candidate) to a 3 month minimum trial of at least one non-biologic systemic agent (i.e., immunosuppressives, retinoic acid derivatives, and/or methotrexate); **AND**
- Patient did not respond adequately (or is not a candidate*) to a 3 month minimum trial of phototherapy (i.e., psoralens with UVA light (PUVA) OR UVB with coal tar or dithranol)

Pediatric Plaque Psoriasis † ^{1,13,26,27,32-34}

- Patient is at least 6 years of age; **AND**
- Documented moderate to severe plaque psoriasis for at least 6 months with at least one of the following:
 - Involvement of at least 3% of body surface area (BSA); **OR**
 - Psoriasis Area and Severity Index (PASI) score of 10 or greater; **OR**
 - Incapacitation or serious emotional consequences due to plaque location (i.e., hands, feet, head and neck, or genitalia, etc.) or with intractable pruritus; **AND**
- Patient did not respond adequately (or is not a candidate) to a 4 week minimum trial of topical agents (i.e., anthralin, coal tar preparations, corticosteroids, emollients, immunosuppressives, keratolytics, retinoic acid derivatives, and/or Vitamin D analogues); **AND**

- Patient did not respond adequately (or is not a candidate) to a 3 month minimum trial of at least one non-biologic systemic agent (i.e., immunosuppressives, retinoic acid derivatives, and/or methotrexate); **AND**
- Patient did not respond adequately (or is not a candidate*) to a 3 month minimum trial of phototherapy (i.e., psoralens with UVA light (PUVA) OR UVB with coal tar or dithranol)

Psoriatic Arthritis (PsA) † 1,5,12,28,35

- Documented moderate to severe active disease; **AND**
 - For patients with predominantly axial disease OR active enthesitis, a trial and failure of at least a 4 week trial of ONE non-steroidal anti-inflammatory agent (NSAID), unless use is contraindicated; **OR**
 - For patients with peripheral arthritis or dactylitis, a trial and failure of at least a 3 month trial of ONE oral disease-modifying anti-rheumatic agent (DMARD) such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, etc.

Note: Patients new to therapy must initiate treatment at the lower dosing regimen of the 150 mg dose before increasing to the 300 mg dose (unless they have co-existent plaque psoriasis)

Ankylosing Spondylitis † 1,11,30

- Documented active disease; **AND**
- Patient had an adequate trial and failure of at least TWO (2) non-steroidal anti-inflammatory agents (NSAIDs) over 4 weeks (in total), unless use is contraindicated

Note: Patients new to therapy must initiate treatment at the lower dosing regimen of the 150 mg dose before increasing to the 300 mg dose

Non-radiographic Axial Spondyloarthritis (nr-axSpA) † 1,30,31

- Patient has objective signs of inflammation noted by an elevation of C-reactive protein (CRP) above the upper limit of normal and/or sacroiliitis on magnetic resonance imaging (MRI) without definitive radiographic evidence of structural damage on sacroiliac joints; **AND**
- Patient has active disease as defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4 and spinal pain ≥ 40 on the Visual Analog Scale (VAS); **AND**
- Patient had an adequate trial and failure of at least TWO (2) non-steroidal anti-inflammatory agents (NSAIDs), unless use is contraindicated

***Examples of contraindications to phototherapy (PUVA or UVB) include the following: 23,24**

- Xeroderma pigmentosum
- Pregnancy or lactation (*PUVA only*)
- Lupus Erythematosus
- History of one of the following: photosensitivity diseases (e.g., chronic actinic dermatitis, solar urticaria), melanoma, non-melanoma skin cancer, extensive solar damage (*PUVA only*), or treatment with arsenic or ionizing radiation
- Immunosuppression in an organ transplant patient (*UVB only*)

- | |
|--|
| <ul style="list-style-type: none">- Photosensitizing medications (<i>PUVA only</i>)- Severe liver, renal, or cardiac disease (<i>PUVA only</i>) |
|--|

† FDA Approved Indication(s); ‡ Compendia recommended indication; Ⓢ Orphan Drug

IV. Renewal Criteria ¹

Coverage can be renewed based upon the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe exacerbations or new onset of inflammatory bowel disease, severe infections, and anaphylactic or other serious allergic reactions, etc.; **AND**

Plaque Psoriasis ^{10,26}

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as redness, thickness, scaliness, and/or the amount of surface area involvement (a total BSA involvement $\leq 1\%$), and/or an improvement on a disease activity scoring tool [e.g. a 75% reduction in the PASI score from when treatment started (PASI 75) or a 50% reduction in the PASI score (PASI 50) and a four-point reduction in the DLQI from when treatment started.]

Pediatric Plaque Psoriasis ^{10,27}

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as redness, thickness, scaliness, and/or the amount of surface area involvement (a total BSA involvement $\leq 1\%$), and/or an improvement on a disease activity scoring tool [e.g. a 75% reduction in the PASI score from when treatment started (PASI 75) or a 50% reduction in the PASI score (PASI 50) and a four-point reduction in the cDLQI from when treatment started.]

Psoriatic Arthritis ⁹

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as the number of tender and swollen joint counts and/or an improvement on a disease activity scoring tool [e.g. defined as an improvement in at least 2 of the 4 Psoriatic Arthritis Response Criteria (PsARC), 1 of which must be joint tenderness or swelling score, with no worsening in any of the 4 criteria.]; **AND**
- Dose escalation (up to the maximum dose and frequency specified below) may occur upon clinical review on a case by case basis provided that the patient has:
 - Shown an initial improvement or response to therapy; **AND**
 - Responded to therapy (by treatment week 8) with subsequent loss of response or continued active disease; **AND**

- Received loading doses and a minimum of one maintenance dose at the dose and interval specified below; **OR**
- Received a minimum of two maintenance doses at the dose and interval specified below

Ankylosing Spondylitis ¹¹

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as total back pain, physical function, morning stiffness, and/or an improvement on a disease activity scoring tool [e.g. ≥ 1.1 improvement on the Ankylosing Spondylitis Disease Activity Score (ASDAS) or an improvement of ≥ 2 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)]; **AND**
- Dose escalation (up to the maximum dose and frequency specified below) may occur upon clinical review on a case by case basis provided that the patient has:
 - Shown an initial improvement or response to therapy; **AND**
 - Responded to therapy (by treatment week 8) with subsequent loss of response or continued active disease; **AND**
 - Received loading doses and a minimum of one maintenance dose at the dose and interval specified below; **OR**
 - Received a minimum of two maintenance doses at the dose and interval specified below

Non-radiographic Axial Spondyloarthritis ^{1,22}

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as total back pain, physical function, reduction of C-reactive protein, and/or an improvement on a disease activity scoring tool [e.g. ≥ 1.1 improvement on the Ankylosing Spondylitis Disease Activity Score (ASDAS), achievement of an ASDAS-Major Improvement (ASDAS-MI e.g. improvement of ≥ 2.0 in the ASDAS and/or reaching the lowest possible ASDAS), improvement of ≥ 2 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), improvement of the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) score from baseline, or an ASAS40 response (defined as a $\geq 40\%$ improvement and an absolute improvement from baseline of ≥ 2 units in ≥ 3 of 4 domains without any worsening in the remaining domain)].

V. Dosage/Administration ¹

Indication	Dose
Plaque Psoriasis	<p><u>Adults</u></p> <p>300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dose is given as 2 subcutaneous injections of 150 mg. For some patients, a dosage of 150 mg may be acceptable.</p>
	<p><u>Pediatric Patients > 6 years of age</u></p> <ul style="list-style-type: none"> ▪ Weight < 50 kg: 75 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 75 mg every 4 weeks

Indication	Dose
	<ul style="list-style-type: none"> Weight \geq 50 kg: 150 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks
Psoriatic Arthritis with co-existent plaque psoriasis	300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dose is given as 2 subcutaneous injections of 150 mg. For some patients, a dosage of 150 mg may be acceptable.
Psoriatic Arthritis	<p><u>With loading dose:</u> 150 mg by subcutaneous injection at Weeks 0, 1, 2, 3, & 4 and every 4 weeks thereafter</p> <p><u>Without a loading dose:</u> 150 mg by subcutaneous injection every 4 weeks</p> <p>Note: Cosentyx may be administered with or without a loading dose for this indication. If the patient continues to have active psoriatic arthritis, increasing the dose to 300 mg may be considered.</p>
Ankylosing spondylitis	<p><u>With loading dose:</u> 150 mg by subcutaneous injection at Weeks 0, 1, 2, 3, & 4 and every 4 weeks thereafter</p> <p><u>Without a loading dose:</u> 150 mg by subcutaneous injection every 4 weeks</p> <p>Note: Cosentyx may be administered with or without a loading dose for this indication. If the patient continues to have active ankylosing spondylitis, increasing the dose to 300 mg may be considered.</p>
Non-Radiographic Axial Spondyloarthritis	<p><u>With loading dose:</u> 150 mg by subcutaneous injection at Weeks 0, 1, 2, 3, & 4 and every 4 weeks thereafter</p> <p><u>Without a loading dose:</u> 150 mg by subcutaneous injection every 4 weeks</p> <p>Note: Cosentyx may be administered with or without a loading dose for this indication.</p>

VI. Billing Code/Availability Information

HCP/PCS Code:

- J3590 – Unclassified biologics
- C9399 – Unclassified drugs or biologicals (*Hospital Outpatient Use ONLY*)

NDC:

- Cosentyx 150 mg/mL Sensoready Pen (carton of 1 or 2): 00078-0639-xx
- Cosentyx 150 mg/mL prefilled syringe (carton of 1 or 2): 00078-0639-xx

- Cosentyx 75 mg/mL prefilled syringe (for pediatric patients less than 50 kg; carton of 1): 0078-1056-xx
- Cosentyx 150 mg lyophilized powder in a single-use vial (HCP use only): 00078-0657-xx

VII. References

1. Cosentyx [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; May 2021. Accessed June 2021.
2. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. *N Engl J Med*. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
3. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. *Arch Dermatol*. 2012 Jan;148(1):95-102.
4. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2008 May;58(5):826-50. doi: 10.1016/j.jaad.2008.02.039.
5. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. *J Am Acad Dermatol* 2008 May;58(5):851-64.
6. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis*. 2015 Dec 7. pii: annrheumdis-2015-208337. doi: 10.1136/annrheumdis-2015-208337.
7. Ward MM, Deodhar, A, Akl, EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2015 Sep 24. doi: 10.1002/art.39298.
8. Smith CH, Jabbar-Lopez ZK, Yiu ZK, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. *Br J Dermatol*. 2017 Sep;177(3):628-636. doi: 10.1111/bjd.15665.
9. National Institute for Health and Care Excellence. NICE 2017. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. Published 24 May 2017. Technology Appraisal Guidance [TA445]. <https://www.nice.org.uk/guidance/TA445/chapter/1-Recommendations>. Accessed June 2018.
10. Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. *J Am Acad Dermatol*. 2017 Feb; 76(2):290-298. doi: 10.1016/j.jaad.2016.10.017.

11. Van Der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Annals of the Rheumatic Diseases* Published Online First: 13 January 2017. doi: 10.1136/annrheumdis-2016-210770.
12. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheumatol*. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726.
13. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019 Feb 13. pii: S0190-9622(18)33001-9. <https://doi.org/10.1016/j.jaad.2018.11.057>.
14. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). *Br J Dermatol* 2015; 172:484.
15. Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). *J Eur Acad Dermatol Venereol* 2015; 29:1082.
16. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2015; 386:1137.
17. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. *N Engl J Med* 2015; 373:1329.
18. Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. *Ann Rheum Dis*. 2018;77(6):890–897. doi:10.1136/annrheumdis-2017-212687.
19. Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. *Ann Rheum Dis* 2017; 76:571.
20. Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. *N Engl J Med* 2015; 373:2534.
21. Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. *Arthritis Res Ther* 2017; 19:285.
22. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016 Mar 16 - . Identifier NCT02696031, Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis (PREVENT); 2016 Mar 2. Available from: <http://clinicaltrials.gov/ct/show/NCT00287391?order=1>
23. Richard EG. (2021). Psoralen plus ultraviolet A (PUVA) photochemotherapy. In Elmets CA, Corona R (Eds.), *UptoDate*. Available from <https://www.uptodate.com/contents/psoralen-plus-ultraviolet-a-puva>

photochemotherapy?sectionName=Skin%20cancer&search=psoriasis%20phototherapy&topicRef=5666&anchor=H31513976&source=see_link#H2099103.

24. Honigsman H. (2020). UVB therapy (broadband and narrowband). In Elmets CA, Corona R (Eds.), *UptoDate*. Available from https://www.uptodate.com/contents/uvb-therapy-broadband-and-narrowband?sectionName=SHORT-%20AND%20LONG-TERM%20ADVERSE%20EFFECTS&search=psoriasis%20phototherapy&topicRef=5666&anchor=H10844620&source=see_link#H10844627.
25. Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. *J Eur Acad Dermatol Venereol*. 2021 Apr;35(4):938-947. doi: 10.1111/jdv.17002.
26. Smith CH, Yiu ZZN, Bale T, et al; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. *Br J Dermatol*. 2020 Oct;183(4):628-637. doi: 10.1111/bjd.19039.
27. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. *J Am Acad Dermatol*. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049.
28. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis*. 2020 Jun;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159.
29. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). *Arthritis Care Res (Hoboken)*. 2011 Nov;63 Suppl 11:S64-85. doi: 10.1002/acr.20577.
30. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042.
31. Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. *Arthritis Rheumatol*. 2021 Jan;73(1):110-120. doi: 10.1002/art.41477.

32. National Institute for Health and Care Excellence. NICE 2017. Psoriasis: assessment and management. Published 24 October 2012. Clinical guideline [CG153]. <https://www.nice.org.uk/guidance/CG153>. Accessed June 2021.
33. National Institute for Health and Care Excellence. NICE 2013. Psoriasis. Published 06 August 2013. Quality standard [QS40]. <https://www.nice.org.uk/guidance/qs40>. Accessed June 2021.
34. Elmetts CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. *J Am Acad Dermatol*. 2019 Sep;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042.
35. American Academy of Dermatology Work Group. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol*. 2011 Jul;65(1):137-74. doi: 10.1016/j.jaad.2010.11.055.

Appendix 1 – Covered Diagnosis Codes

ICD-10 Codes	ICD-10 Description
L40.0	Psoriasis vulgaris
L40.50	Arthropathic psoriasis, unspecified
L40.51	Distal interphalangeal psoriatic arthropathy
L40.52	Psoriatic arthritis mutilans
L40.53	Psoriatic spondylitis
L40.59	Other psoriatic arthropathy
M45.0	Ankylosing spondylitis of multiple sites in spine
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region
M45.2	Ankylosing spondylitis of cervical region
M45.3	Ankylosing spondylitis of cervicothoracic region
M45.4	Ankylosing spondylitis of thoracic region
M45.5	Ankylosing spondylitis of thoracolumbar region
M45.6	Ankylosing spondylitis lumbar region
M45.7	Ankylosing spondylitis of lumbosacral region
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region
M45.9	Ankylosing spondylitis of unspecified sites in spine
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region
M46.82	Other specified inflammatory spondylopathies, cervical region
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region
M46.84	Other specified inflammatory spondylopathies, thoracic region
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region

COSENTYX® (secukinumab) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management

ICD-10 Codes	ICD-10 Description
M46.86	Other specified inflammatory spondylopathies, lumbar region
M46.87	Other specified inflammatory spondylopathies, lumbosacral region
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC